The president’s executive order is intended to accelerate research into the compounds’ efficacy in treating mental health disorders like severe depression and PTSD. By Andrew Jacobs and Noah Daly ...

President Donald Trump on Saturday directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine, which recently has been embraced by combat veterans and ...

President Donald Trump on Saturday directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine, which recently has been embraced by combat veterans and ...

President Trump has signed an executive order to ease research restrictions on psychedelics, including the drug ibogaine, which is used in some countries to treat post-traumatic stress disorder.

The hotel ballroom was packed to near capacity with scientists when Susan Yanovski arrived. Despite being 10 minutes early, she had to manoeuvre her way to one of the few empty seats near the back.

On April 18, President Donald Trump signed an executive order intended to accelerate the development of psychedelic drugs as medical treatments. The order calls for the Food and Drug Administration ...

REMOVING BARRIERS TO PSYCHEDELIC DRUGS AS POTENTIAL TREATMENT FOR SERIOUS MENTAL ILLNESS: Today, President Donald J. Trump signed an Executive Order that will accelerate access to treatments for ...

Drug safety relates to the potential for adverse effects related to the administration of drugs. Efforts to establish the safely profile of drugs begin early in their development, with in vitro and in ...